Subcutaneous allergen immunotherapy in the treatment of atopic dermatitis
We report atopic dermatitis treated successfully with allergen immunotherapy.
For this ‘From the Pages of Allergy Watch’ reviews from several recent issues were selected which review articles about Allergic Skin Diseases, the focus of this issue of the Annals. The first article describes a unique minimally invasive method of skin tape stripping to identify infants with atopic derm atitis who are at increased risk for food allergy. The next study investigates the difference between IgE sensitivity and clinical reactivity to foods in children with atopic dermatitis. The last investigates the impact of UV light exposure and the development of atopic dermatitis in infancy.
Atopic dermatitis (AD) is associated with increased systemic inflammation and cardiovascular risk. While previous studies showed increased inflammatory proteins in the blood of AD patients, detailed comparison among AD patients of different ages is unavailable.
Filaggrin is a major epidermal protein that has been shown to be a key player in the pathogenesis of AD and allergic disease. While filaggrin is a significant genetic risk factor for AD, it is also an important disease modifier in AD. Patients with filaggrin related AD and asthma have more frequent hospital admissions and long-term medication costs. Atopic dermatitis patients with FLG mutations are more frequently affected by reduced health related quality of life when compared to AD patients with wild-type FLG.
Disclosures: E. Guttman-Yassky received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; her institution received grants from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, N...
PMID: 31622670 [PubMed - as supplied by publisher]
PMID: 31622669 [PubMed - as supplied by publisher]
Abstract BACKGROUND: Atopic dermatitis (AD) is associated with increased systemic inflammation and cardiovascular risk. While previous studies showed increased inflammatory proteins in the blood of AD patients, detailed comparison among AD patients of different ages is unavailable. OBJECTIVE: To characterize the blood proteomic signature of AD patients as a function of age. Methods We used the OLINK high-throughput proteomic assay to measure serum inflammatory and cardiovascular risk proteins in 71 moderate-to-severe AD patients from three agegroups (18-40 [n=26], 41-60 [n=24],>60 [n=21]), compared to 37 a...
CONCLUSIONS: In the assessed population, there were significantly higher levels among those with positive screening tests and PhInf showed better performance in the identification of sensitized individuals, regardless of age. This is the first study to evaluate Phadiatop and Phadiatop Infant in the same population. PMID: 31601506 [PubMed - as supplied by publisher]
CONCLUSIONS: UR-SCIT with tyrosine-adsorbed HDM extract conducted in an outpatient clinic was tolerable in patients with AD and AR. UR-SCIT can be a useful method to start a SCIT in patients with AD and AR. PMID: 31552719 [PubMed]
In this study, we investigated the clinical manifestations and risk factors for anaphylaxis in PFAS in Korean patients with pollinosis. MATERIALS AND METHODS: Data were obtained from a nationwide cross-sectional study that previously reported on PFAS in Korean patients with pollinosis. Data from 273 patients with PFAS were collected, including demographics, list of culprit fruits and vegetables, and clinical manifestations of food allergy. We analyzed 27 anaphylaxis patients and compared them with patients with PFAS with oropharyngeal symptoms only (n=130). RESULTS: The most common cause of anaphylaxis in PFAS wa...